PEGBIO CO-B (02565.HK): Core GLP-1 Drug Added to 2026 National Reimbursement List

On 15 Nov 2026, PEGBIO CO-B (02565.HK) said its once-weekly GLP-1 injection was added to China's 2026 national reimbursement list.

NewTimeSpace News: On 15 November 2026, PegBio Co., Ltd. (stock code: 2565) published a voluntary announcement that its self-developed innovative drug, a once-weekly long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) injection, has been added to the 2026 edition of the National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work Injury Insurance issued by China's National Healthcare Security Administration.

The product, the Group's first approved innovative drug, is a Class 1 innovative drug in China approved by the National Medical Products Administration in November 2025 for glycaemic control in adults with type 2 diabetes. It offers differentiated clinical features, including treatment from the starting dose without the need for dose titration. Key clinical results showed sustained and stable glycaemic control.

The inclusion marks a breakthrough in access to the national healthcare security system for the Group's first commercialised innovative product, and a milestone in its shift from innovative research to scaled commercialisation, the Company said. The Group has built a commercialisation network for the product and will work with partners to advance hospital access, channel coverage and clinical use.

The Company cautioned that actual commercial performance may be affected by market conditions, market access, commercialisation progress and other factors.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.